2005
DOI: 10.1053/j.ajkd.2004.09.005
|View full text |Cite
|
Sign up to set email alerts
|

Chronic kidney disease: Stemming the global tide

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
13
1
5

Year Published

2006
2006
2019
2019

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 25 publications
(19 citation statements)
references
References 45 publications
0
13
1
5
Order By: Relevance
“…Approximately 11.5% of US adults have CKD [Levey et al, ], and its prevalence is increasing in the US [Coresh et al, ] and in many other countries [Bello et al, ; Nwankwo et al, ]. Overall Medicare expenditures for CKD reached $41 billion in 2010 according to the US Renal Data System [US Renal Data System, ].…”
Section: Introductionmentioning
confidence: 99%
“…Approximately 11.5% of US adults have CKD [Levey et al, ], and its prevalence is increasing in the US [Coresh et al, ] and in many other countries [Bello et al, ; Nwankwo et al, ]. Overall Medicare expenditures for CKD reached $41 billion in 2010 according to the US Renal Data System [US Renal Data System, ].…”
Section: Introductionmentioning
confidence: 99%
“…Finally, it is recommended that evaluation of environmental and occupational nephrotoxins like lead be incorporated into programs for the prevention of CKD, especially in developing countries where lead exposure and toxicity still remain largely unchecked 2,7-9 and the prevalence and burden of CKD is increasing. 9,112 …”
Section: Discussionmentioning
confidence: 98%
“…15 Lead which is an environmental and occupational nephrotoxin should be evaluated in programs for the prevention of CKD, especially in developing countries where lead exposure still remain largely unchecked and the prevalence and burden of CKD is increasing. 16,17 Chelation therapy (DMSA/Calcium EDTA) can be considered for individuals with blood lead levels 4100 mcg/dL, and should also be considered for levels between 80 to 100 mcg/dL in asymptomatic individuals and for blood lead levels between 50 to 80 mcg/dL in individuals with lead- related symptoms. 18 Chelation should be considered when exposure has been definitively curtailed, because its use in the presence of continuing exposure may result in enhanced absorption of lead and worsening, rather than amelioration of toxicity/kidney injury.…”
Section: Discussionmentioning
confidence: 99%